United States regulators have granted accelerated approval to a new treatment designed to reduce the need for repeated surgery in adults living with a rare airway disease. The therapy, called Voceryq, is intended for people with recurrent respiratory papillomatosis, a condition in which wart-like growths keep returning in the airways. It is the first plasmid DNA-based immunotherapy to win approval in the United States.
A Disease Defined by Repeat Surgery
Recurrent respiratory papillomatosis, often shortened to RRP, is an uncommon disorder in which benign growths develop in the respiratory tract, most often on the vocal cords and in the larynx. The growths can narrow the airway, change the voice, and in serious cases make breathing difficult. Because the growths tend to come back after they are removed, many patients undergo surgery again and again over the course of their lives, sometimes several times a year. Until now, managing the disease has largely meant managing that cycle of removal and regrowth. A treatment that slows the return of growths, even partly, could therefore change daily life for patients substantially.
What the Study Found
The Food and Drug Administration announced its decision on Friday. According to the agency, the approval drew on an open-label study involving 32 adults with the condition. Among the 26 participants who had needed at least three surgeries in the twelve months before treatment, seven, or 27 percent, required no surgery at all during the first year after receiving the therapy. Regulators were careful to describe what the result does and does not mean. Requiring fewer operations is a meaningful outcome for a disease defined by repeat procedures, but the approval does not establish that the treatment is a cure, and the study was small and had no comparison group receiving a placebo.
Approval With Conditions Attached
Voceryq reached patients through the FDA’s accelerated approval pathway, which allows promising treatments for serious conditions to be authorised on early evidence while further research continues. As a condition, the manufacturer, Inovio, must run additional clinical trials to confirm that the benefit seen in the first study is real and lasting. The company has said it must submit a draft protocol for that confirmatory study by the end of this year, with a final protocol expected to be agreed by mid-2027. The firm also says it expects orders and shipments to begin in roughly sixty days, with fuller commercial rollout in early 2027, although those are company forecasts rather than guarantees.
For the small community of people living with RRP, the decision is a notable milestone: the first therapy aimed not at removing growths, but at helping the immune system keep them from coming back. Whether it delivers on that promise will depend on the larger trials still to come.
